{
    "clinical_study": {
        "@rank": "115863", 
        "acronym": "DECODIAB", 
        "brief_summary": {
            "textblock": "The main objective of the study is to understand the pathophysiological mechanisms involved\n      in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2\n      diabetes risk in the population of patients with pre-diabetes."
        }, 
        "brief_title": "Screening and Understanding of the Pre-diabetes: DECODIAB", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Pre-diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients (\u226518 years)\n\n          -  Subjects with diabetes risk score \u2265 12 or with impaired fasting glucose: blood\n             glucose \u2265 1.10 g/l and < 1 .26 g/L\n\n          -  And with impaired fasting glucose : blood glucose \u2265 1.10 g/l and < 1 .26 g/L ; or\n             blood glucose \u2265 1g/l and < 1,1 g/L WITH HbA1C \u2265 6,5%\n\n          -  Signed informed consent\n\n          -  Subjects affiliated with an appropriate social security system\n\n        Exclusion Criteria:\n\n          -  Fasting glycemia \u2265 1.26 g/l\n\n          -  Fasting glycemia \u2264 1.10 g/l AND HbA1C < 6,5%\n\n          -  Fasting glycemia < 1 g/l\n\n          -  Subjects previously treated with oral anti-diabetic: metformin, glitazones,\n             inhibitors of \u03b1-glucosidase, sulfonylurea, repaglinide, inhibitors of DPP-IV.\n\n          -  Subjects previously treated with insulin, except  gestational diabetes\n\n          -  Severe coagulation disorders\n\n          -  Thrombocytopenia < 100 000/mm 3\n\n          -  Severe psychiatric disorders\n\n          -  Severe renal insufficiency (creatinine clearance < 30 ml/min)\n\n          -  Severe hepatic insufficiency\n\n          -  Alcohol abuse (> 30g/j)\n\n          -  Contra-indication in the realization of the local anesthetic\n\n          -  Subject unable to follow the study during the 5 years of follow-up\n\n          -  Subject exclusion period in a previous study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739868", 
            "org_study_id": "09/9-A"
        }, 
        "intervention": {
            "description": "3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:\n1 visit the first year (inclusion visit)\n1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes\n1 intermediary visit (in 3 years) or activated by the following conditions:\nEscalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)\nNormalization of the glycemia (fasting blood glucose < 1 g/l)", 
            "intervention_name": "Biopsies of muscular and fat tissue", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pre-diabetes", 
            "Type 2 diabetes", 
            "Biomarkers", 
            "Diabetes risk score"
        ], 
        "lastchanged_date": "November 28, 2012", 
        "location": {
            "contact": {
                "last_name": "Bertrand CARIOU, Pr", 
                "phone": "02 53 48 27 10"
            }, 
            "facility": {
                "address": {
                    "city": "Nantes", 
                    "country": "France"
                }, 
                "name": "Nantes University Hospital"
            }, 
            "investigator": {
                "last_name": "Bertrand CARIOU, Pr", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "official_title": "Screening and Understanding of the Pre-diabetes: DECODIAB", 
        "overall_contact": {
            "last_name": "Bertrand CARIOU, Pr", 
            "phone": "02 53 48 27 10"
        }, 
        "overall_official": {
            "affiliation": "Nantes University Hospital", 
            "last_name": "Bertrand CARIOU, Pr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The main objective of the study is to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in the population of patients with pre-diabetes", 
            "measure": "To identify new biomarkers", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739868"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To identify new therapeutic targets for the prevention of the appearance of the diabetes in the population of patients with pre-diabetes", 
                "measure": "To identify new therapeutic targets", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "To connect identified biomarkers with the degree of insulinoresistance (HOMA-R) and with \u03b2 pancreatic function (IOG) in the population of patients with pre-diabetes.", 
                "measure": "To connect identified biomarkers with the degree of insulinoresistance", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "To evaluate the interest of the Diabetes Risk Score in identifying subjects with pre-diabetes in the French population", 
                "measure": "Number of patients with high Diabetes Risk Score and pre-diabetes", 
                "safety_issue": "No"
            }, 
            {
                "description": "To evaluate the prevalence of others cardiovascular risk factors associated with pre-diabetes: dyslipidemia, hypertension, metabolic liver disease", 
                "measure": "Number of patients with others cardiovascular risk factors", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Intervention Model: Single Group Assignment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}